2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Recurrence
5
Neoplasms, Plasma Cell
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Primary Myelofibrosis
2
Oligodendroglioma
2
Neuroblastoma
2
Myeloproliferative Disorders
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Astrocytoma
2
Thrombocytosis
1
Thrombocythemia, Essential
1
Sezary Syndrome
1
Rhabdomyosarcoma
1
Polycythemia Vera
1
Polycythemia
1
Osteosarcoma
1
Optic Nerve Glioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Neuroepithelial
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
fludarabine phosphate
25
Cyclophosphamide
24
Peripheral Blood Stem Cell Transplantation
23
Busulfan
17
Tacrolimus
15
Methotrexate
13
Cyclosporine
13
ruxolitinib
12
Whole-Body Irradiation
12
Mycophenolic Acid
12
Antilymphocyte Serum
11
Filgrastim
8
Decitabine
7
fludarabine
6
Etoposide
6
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
6
peginterferon alfa-2a
5
Radiotherapy
5
Methylprednisolone
5
Cytarabine
5
Carboplatin
5
Prednisone
4
Melphalan
4
Flow Cytometry
4
Biopsy
4
Aspirin
4
givinostat hydrochloride
3
givinostat
3
bomedemstat
3
anagrelide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thrombocythemia, Essential
×
imetelstat
×
Clear all
NCT01243073
2016-01-26
ET/PV
Geron Corporation
Phase 2
Completed
20 enrolled